Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  BIOALLIANCE PHARMA    BIO   FR0010095596

BIOALLIANCE PHARMA

 (BIO)
444
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
05/13/2013 05/14/2013 05/15/2013 05/16/2013 05/17/2013 Date
4.48(c) 4.36(c) 4.27(c) 4.28(c) 4.28(c) Last
30 458 224 020 69 582 48 076 37 827 Volume
+0.67% -2.68% -2.06% +0.23% 0.00% Change
More quotes
Company
BioAlliance Pharma specializes in researching, developing, and marketing therapeutic products used to control drug resistance. The company's products are used primarily in treating cancer, the AIDS virus (HIV), and infectious diseases. Manufacturing, packaging, and labeling are handled by... 
Read more
More about the company
Chart BIOALLIANCE PHARMA
Duration : Period :
BIOALLIANCE PHARMA Technical Analysis Chart | BIO | FR0010095596 | 4-Traders
Full-screen chart
Financials (€)
Sales 2013 29,0 M
EBIT 2013 13,4 M
Net income 2013 13,4 M
Finance 2013 56,0 M
Yield 2013 -
Sales 2014 29,8 M
EBIT 2014 14,2 M
Net income 2014 14,1 M
Finance 2014 71,4 M
Yield 2014 -
PER 2013 5,35
PER 2014 5,35
EV / Sales 2013 0,75x
EV / Sales 2014 0,21x
Capitalization 77,7 M
More Financials
Latest news on BIOALLIANCE PHARMA
4d ago BIOALLIANCE PHARMA: announces DSMB second positive recommendation to continue i..
5d ago BIOALLIANCE PHARMA: Disclosure of total number of voting rights and number of s..
6d ago BIOALLIANCE PHARMA: annonce la recommandation positive du comité d’experts pour..
6d ago BIOALLIANCE PHARMA: announces DSMB second positive recommendation to continue i..
04/19 BIOALLIANCE PHARMA: SA : Publication of the 2012 Registration Document
04/15 BIOALLIANCE PHARMA: Updates on Major Achievements of 2012 and Publishes Its 201..
04/15 BIOALLIANCE PHARMA: BioAlliance Pharma's Sitavig® Receives Market Authorization..
04/10BIOALLIANCE PHARMA SA: quaterly earnings release
04/08 BIOALLIANCE PHARMA: Disclosure of Total Number of Voting Rights and Number of S..
03/12 BIOALLIANCE PHARMA: pursues the development plan of its Loramyc® in Japan throu..
03/12 BIOALLIANCE PHARMA: Pursues the Development Plan of Its Loramyc® in Japan Throu..
03/04 BIOALLIANCE PHARMA: Disclosure of Total Number of Voting Rights and Number of S..
More news
Forum BIOALLIANCE PHARMA
Be the first to post a message on BIOALLIANCE PHARMA
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Technical analysis
Income Statement Evolution
BIOALLIANCE PHARMA : Income Statement Evolution
More Financials
EPS Revisions
BIOALLIANCE PHARMA : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF
My Watchlist|My Portfolio
4-traders.com :
About :
Copyright © 2013 Surperformance. All rights reserved.